Surgalign Spine Technologies  



Surgalign: empowering surgeons, advancing spine care.

Surgalign Holdings, Inc. is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company is building off a legacy of high quality and differentiated products, and continues to invest in clinically validated innovation to deliver better surgical outcomes and improve patient’s lives. Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. Surgalign, a member of AdvaMed, is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Marquette, MI, and Wurmlingen, Germany. 

See their team of highly experienced leaders here

Learn more at www.surgalign.com and connect on LinkedIn and Facebook.

Brands: Fortilink® IBF Systems w/ TETRAfuse® 3D Technology, coflex® Interlaminar Stabilization®, SImmetry® SI Joint Fusion System, nanOss® Advanced Bone Graft Substitutes, Streamline® Spinal Fixation Systems


 Videos

TETRAfuse® 3D Technology Wicking Video
SImmetry® Surgeon Animation
coflex® Procedural Animation

 Press Releases

  • JUL 20, 2020

    Jonathon Singer
    Investor and Media Contact
    jsinger@rtix.com
    +1 877-343-6832

    • After-tax proceeds from the OEM sale will be utilized to repay all outstanding indebtedness and redeem outstanding Series A Convertible Preferred Stock
    • Company has been renamed Surgalign Holdings, Inc and will trade under the ticker “SRGA” effective July 23, 2020

    DEERFIELD, Ill., July 20, 2020 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc. (formerly RTI Surgical Holdings, Inc.) (Nasdaq: RTIX), a global surgical implant company, today announced the closing of the sale of the OEM business, effective July 20, 2020, for a total consideration of $440 million, paid in cash.

    The Company has fully repaid all of its outstanding indebtedness, including the $80 million revolving line of credit with JP Morgan Chase Bank and both the $100 million term loan and $30 million incremental term loan commitment with Ares Capital Corporation. The Company will also redeem all of the outstanding shares of Series A Convertible Preferred Stock for total cash consideration of approximately $67 million.  After giving effect to the repayment of debt and transaction expenses, the Company has approximately $190 million in cash and cash equivalents, which will be reduced by approximately $137 million after the Company redeems the Series A Convertible Preferred and pays tax on the gain from the OEM sale, both of which are expected to occur by September 30, 2020.

    Effective immediately, the Company’s name has changed to Surgalign Holdings, Inc., and the Company’s ticker symbol on the NASDAQ will change to “SRGA.” Trading under the new ticker symbol is expected to begin on Thursday, July 23, 2020.

    As previously announced, the Board of Directors appointed Terry M. Rich as the Company’s new President and CEO, effective immediately. Mr. Rich previously served as RTI’s President of Global Spine. Mr. Rich’s appointment follows Camille Farhat retiring from his role as President and CEO after completion of the sale of the Company’s OEM business.  Mr. Farhat will remain employed by the Company for a brief period of time to assist with the transition of responsibilities.  Mr. Rich also replaced Mr. Farhat on the Company’s Board of Directors.

    “I am excited to lead Surgalign as we complete our transition to a global pure-play spine company,” said Terry Rich, President and CEO, Surgalign. “We believe we have a tremendous foundation that I have been a part of building over the last eight months, and with the recent addition of highly experienced leaders, as well as the financial flexibility provided by the sale of the OEM business, we will pursue our long term goal of driving double digit topline growth through our strategy of build, innovate, and acquire.”

    As previously announced, the Board of Directors appointed Jonathon M. Singer as the Company’s new Chief Operating Officer, effective immediately. Mr. Singer will continue to serve as the Company’s Chief Financial Officer.

    Also as previously announced, the Board of Directors appointed Stuart F. Simpson as the Company’s new Chairman of the Board and Curt Selquist as the Company’s Lead Independent Director of the Board, effective immediately.

    About Surgalign Holdings, Inc.

    Surgalign Holdings, Inc. is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company is building off a legacy of high quality and differentiated products, and continues to invest in clinically validated innovation to deliver better surgical outcomes and improve patient’s lives.  Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors.  Surgalign, a member of AdvaMed, is headquartered in Deerfield, Illinois, with commercial, innovation and design centers in San Diego, California, and Wurmlingen, Germany. Learn more at www.surgalign.com and connect on LinkedIn and Twitter.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are not guarantees of future performance and are based on certain assumptions including general economic conditions, as well as those within the Company’s industry, and numerous other factors and risks identified in the Company’s Form 10-K for the fiscal year ended December 31, 2019 and other filings with the SEC. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Important factors that could cause actual results to differ materially from the anticipated results reflected in these forward-looking statements include risks and uncertainties relating to the following: (i) the risk of existing or potential litigation or regulatory action arising from the previously announced internal investigation and its findings or from the failure to timely file the Form 10-K; (ii) the identification of control deficiencies, including material weaknesses in internal control over financial reporting and the impact of the same; (iii) potential reputational damage that the Company has or may suffer as a result of the ultimate findings of the investigation; (iv) general worldwide economic conditions and related uncertainties; (v) the anticipated impact of the COVID-19 novel coronavirus pandemic and the Company’s attempts at mitigation; (vi) the failure by the Company to identify, develop and successfully implement immediate action plans and longer-term strategic initiatives; (vii) our ability to continue production; (viii) the reliability of our supply chain; (ix) our ability to meet obligations under our debt or material agreements; (x) the duration of decreased demand for our products; (xi) our ability to continue to recall furloughed employees; (xii) whether or when the demand for procedures will increase; (xiii) the Company’s access to adequate operating cash flow, trade credit, borrowed funds and capital to fund its operations and pay its obligations as they become due, including the impact of adverse trends or disruption in the global credit and equity markets; (xiv) our financial position and results, total revenue, product revenue, gross margin, and operations; (xv) the risk that shareholder litigation may result in significant costs of defense, indemnification and liability; (xvi) the effect and timing of changes in laws or in governmental regulations; (xviii) any effects resulting from the redemption of our Series A Convertible Preferred stock and (xviii) other risks described in our public filings with the SEC. In particular, any statement that the Company will pursue its long term goal of driving double digit topline growth through its strategy of build, innovate, and acquire is a forward-looking statement.  These factors should be considered carefully and undue reliance should not be placed on the forward-looking statements. Each forward-looking statement in this communication speaks only as of the date of the particular statement. Copies of the Company’s SEC filings may be obtained by contacting the Company or the SEC or by visiting the Company’s website at www.surgalign.com or the SEC’s website at www.sec.gov.  We undertake no obligation to update these forward-looking statements except as may be required by law.

  • SEP 29, 2020

    Commitment to the Promise of Digital Surgery to Improve Patient Outcomes

    Jonathon Singer
    Investor and Media Contact
    jsinger@surgalign.com
    +1 224 303 4651

    Deerfield, Ill., Sept 29, 2020 – Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes, today announces that it has entered into a definitive agreement to acquire Holo Surgical Inc., (‘Holosurgical’), a Chicago-based private technology company developing the revolutionary Augmented Reality and Artificial Intelligence platform (‘ARAI™’), to enable digital spine surgery. Total consideration for the transaction is valued at up to $125 million, consisting of consideration valued at $42 million payable at closing in cash and shares plus potential future milestone payments. The transaction is expected to close during the fourth quarter of 2020, subject to customary closing conditions.

    Holosurgical is developing and preparing for regulatory submission the ARAI™ platform, which the parties believe is the world’s first and most advanced technology designed to automatically segment, identify, and recognize patient anatomy for autonomously assisting the surgeon throughout the case. This system was granted patents as an intelligent anatomical mapping technology designed to assist surgeons by allowing them to remain in safe anatomical zones, and enhancing surgical performance to facilitate improved patient outcomes. The ARAI surgical navigation technology is designed to turn today’s “dumb” surgical tools into tomorrow’s “smart” surgical instruments. Holosurgical was founded in 2015 by virtual and augmented reality expert Prof. Cristian Luciano, PhD, and spine surgeon Dr. Kris Siemionow, MD, PhD, and in 2016 joined by Prof. Paul Lewicki, PhD, a pioneer in artificial intelligence.

    “We are very excited about bringing the innovative surgical platform and world-class team from Holosurgical into our organization,” said Terry Rich, President and Chief Executive Officer of Surgalign Holdings. “A foundational thesis at Surgalign is that digital surgery will enable the next wave of innovation in spine surgery. We wanted to find a partner who was developing truly novel digital technologies that could transform the way spine surgery is performed and support clinical research to demonstrate improved patient outcomes. We believe that with Holosurgical’s ARAI platform in combination with our ongoing research and development efforts, we will have positioned ourselves as a leading digital surgical company in spine.”

    Mr. Rich continued, “In addition to the advanced technology platform, we are thrilled to be adding such a high-caliber team of thought leaders in digital surgery, artificial intelligence, and machine learning. As we look to develop innovative technologies to enable advanced digital surgery, we believe we will benefit from the experience and expertise of the Holosurgical team.”

    “We are thrilled to be joining Surgalign as they seek to revolutionize the way spine surgery is performed and improve patient outcomes,” said Dr. Kris Siemionow, MD, PhD Chief Executive Officer of Holosurgical. “We have a shared vision for what surgery can and should be. With Surgalign’s focus on continued innovation and their well-established commercial infrastructure, we believe that together we can bring truly advanced digital surgery to hospitals, surgeons, and patients worldwide.”

    Strategic Rationale

    • Establishes our commitment to digital surgery. Surgalign’s strategy includes a commitment to digital surgery. By acquiring the Holosurgical platform technology with its thought leading management team, the Company believes it is adding a principal component of our strategic agenda.
    • Provides a highly differentiated technology. An essential premise of Surgalign’s inorganic strategy is “differentiation,” which will allow the Company to engage surgeons, distribution partners, hospitals and outpatient settings with unique solutions. We believe Holosurgical technology leapfrogs any navigation or robotic system currently on the market.
    • Serves as a catalyst to drive new revenue streams. By offering a digital surgical platform, Surgalign intends to accelerate revenue growth and allow for pull through of implants and create new revenue streams through the sale and service of the platform.
    • Enables improved patient outcomes. Surgalign’s primary goal is bringing products to the market that improve surgical outcomes. Surgalign believes the ARAI platform helps surgeons provide patient-specific solutions with advanced artificial intelligence based autonomous pre-operative and intra-operative capabilities, allowing them to perform better surgery and avoid many common complications.

    Transaction Overview

    Under the terms of the agreement, at the closing of the transaction, Surgalign will pay $30 million in cash and issue 6.25 million shares of Surgalign common stock which are valued at approximately $12 million, based on the volume-weighted average trading price of Surgalign’s shares of common stock during the five trading days ended September 25, 2020. In addition, further consideration of up to $83 million may be paid in stock and cash upon achievement of certain regulatory, developmental and commercial milestones. The closing cash payment will be funded through existing cash on the balance sheet. The transaction is expected to close in the fourth quarter, subject to the expiration or early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 and other customary closing conditions.

    Conference Call

    Surgalign will host a conference call and audio webcast at 9:00a.m. ET tomorrow to discuss the transaction. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International), using conference ID 1379825. The webcast can be accessed through the investor section of Surgalign’s website at www.surgalign.com/investors. A replay of the conference call audio webcast will be available on Surgalign’s website for at least one month following the call.

    About Holo Surgical Inc.

    Holosurgical is a digital surgery company focused on improving patient outcomes by bringing Augmented Reality and Artificial Intelligence to the operating room. It was founded in 2015 by virtual and augmented reality expert Prof. Cristian Luciano, PhD, and spine surgeon Dr. Kris Siemionow, MD, PhD, and in 2016 joined by Prof. Paul Lewicki, PhD, a pioneer in artificial intelligence.

    About Surgalign Holdings, Inc.

    Surgalign Holdings, Inc. is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company is building off a legacy of high quality and differentiated products and continues to invest in clinically validated innovation to deliver better surgical outcomes and improve patient’s lives. Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. Surgalign, a member of AdvaMed, is headquartered in Deerfield, IL, with commercial, innovation and design centers in San Diego, CA, Marquette, MI, and Wurmlingen, Germany. Learn more at www.surgalign.com and connect on LinkedIn and Twitter.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are not guarantees of future performance and are based on certain assumptions including general economic conditions, as well as those within the Company’s industry, and numerous other factors and risks identified in the Company’s Form 10-K for the fiscal year ended December 31, 2019 and other filings with the SEC. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Important factors that could cause actual results to differ materially from the anticipated results reflected in these forward-looking statements include risks and uncertainties relating to the following: (i) the risk of existing or potential litigation or regulatory action arising from the previously announced SEC and internal investigations and their findings; (ii) the identification of control deficiencies, including material weaknesses in internal control over financial reporting and the impact of the same; (iii) potential reputational damage that the Company has or may suffer as a result of the findings of the investigations; (iv) general worldwide economic conditions and related uncertainties; (v) the anticipated impact of the COVID-19 novel coronavirus pandemic and the Company’s attempts at mitigation; (vi) the failure by the Company to identify, develop and successfully implement immediate action plans and longer-term strategic initiatives; (vii) the reliability of our supply chain; (viii) our ability to meet obligations under our material agreements; (ix) the duration of decreased demand for our products; (x) whether or when the demand for procedures involving our products will increase; (xi) the Company’s access to adequate operating cash flow, trade credit, borrowed funds and equity capital to fund its operations and pay its obligations as they become due, and the terms on which external financing may be available, including the impact of adverse trends or disruption in the global credit and equity markets; (xii) our financial position and results, total revenue, product revenue, gross margin, and operations; (xiii) the possibility that the proposed acquisition of Holo Surgical Inc. will not be consummated, including as a result of the failure to obtain necessary antitrust approval or the failure of any of the conditions to the acquisition to be satisfied; (xiv) failure to realize, or unexpected costs in seeking to realize, the expected benefits of the proposed acquisition, including the failure of Holo Surgical’s products and services to be satisfactorily developed or achieve applicable regulatory approvals or as a result of the failure to commercialize and distribute Holo Surgical’s products; (xv) the failure to effectively integrate Holo Surgical’s operations with those of the Company; (xvi) the failure to retain key personnel of Holo Surgical; (xvii) the number of shares and amount of cash that will be required in connection with any post-closing milestone payments, including as a result of changes in the trading price of the Company’s common stock and their effect on the amount of cash needed by the Company to fund any post-closing milestone payments in connection with the proposed acquisition; (xviii) the effect of the announcement of the transaction on relationships with customers, suppliers and other third parties; (xix) the diversion of management time and attention on the transaction and subsequent integration if the transaction is consummated; (xx) the effect and timing of changes in laws or in governmental regulations; (xxi) risks resulting from the Company’s reduced cash levels as a result of the recent redemption of Series A Convertible Preferred Stock; and (xii) other risks described in our public filings with the SEC. These factors should be considered carefully, and undue reliance should not be placed on the forward-looking statements. Each forward-looking statement in this communication speaks only as of the date of the particular statement. Copies of the Company’s SEC filings may be obtained by contacting the Company or the SEC or by visiting Surgalign’s website at www.surgalign.com or the SEC’s website at www.sec.gov. We undertake no obligation to update these forward-looking statements except as may be required by law.


 Featured Products

  • SImmetry® SI Joint Fusion System
    The SImmetry system is a minimally invasive SI joint fusion system that uses proven orthopedic principles, including joint decortication, bone grafting and fixation, to achieve true arthrodesis....

  • Minimally invasive surgery using the SImmetry system typically takes less than one hour to perform, has fewer postoperative complications than open SI joint fusion surgery and involves: 

    • < 50cc estimated blood loss1 
    • A small incision—typically only a couple centimeters—on one side of the buttock2 
    • Brief hospital stay3 
    • Potential for short weight-bearing recovery period based on sacroiliac joint fusion postoperative guidelines4 
    • True SI joint arthrodesis5 

    The SImmetry system affords an efficient and effective minimally invasive technique to effect a true arthrodesis of the sacroiliac joint as follows: 

    • Minimally invasive lateral access for safety and control 
    • Joint preparation with the proprietary SImmetry Decorticator® instrument removes cartilage and decorticates opposing joint surfaces 
    • Bone graft delivery to the prepared joint to facilitate fusion 
    • Joint fixation with threaded titanium implants 

    1. Araghi A, et. al. Pain and opioid use outcomes following minimally invasive sacroiliac joint fusion with decortication and bone grafting: The Evolusion Clinical Trial. The Open Orthopaedics Journal, 2017, 11, 1440-1448 
    2. Miller L, et. al. Minimally invasive arthrodesis for chronic sacroiliac joint dysfunction using the SImmetry SI Joint Fusion system: Dove Press. Medical Devices: Evidence and Research, May 7, 2014 
    3. Kube R, et. al. Sacroiliac joint fusion: One year clinical and radiographic results following minimally invasive sacroiliac joint fusion surgery: The Open Orthopaedics Journal, 2016, 10, 679-689 
    4. Dall, B. Post-operative guidelines for sacroiliac joint fusion. Published White Paper 
    5. Cross W, et. al. Evaluation of fusion after minimally invasive sacroiliac joint fusion surgery with decortication: 24-month results. International Society for the Advancement of Spine Surgery. Annual Meeting, April 2017 

  • coflex® Interlaminar Stabilization®
    The coflex® Interlaminar Stabilization® device is a minimally invasive posterior lumbar motion preservation solution that addresses leg and back pain and has proven long-term outcomes for durable pain relief and stability.1...

  • Decompression with interlaminar stabilization using the coflex device is performed through a small, midline incision in the lower back that allows for a minimally invasive approach for treating your lumbar spinal stenosis. The coflex device: 

    • Is inserted directly following a surgical decompression by your spine surgeon 
    • Rests on laminar bone in between two vertebrae, where the “U” is closest to the spinal canal 
    • Maintains foraminal height and off-loads facets 
    • Allows the bones to move in a controlled manner, preserving natural motion 
    • Reduces trauma to your back, decreases the amount of blood loss during surgery, and allows for a shorter hospital or outpatient surgical center stay compared to fusion 

    BENEFITS VS. DECOMPRESSION2 

    Decompression is appropriate for many patients; however, in order for the surgeon to adequately decompress the spine, all bony and neural elements putting pressure on the spinal nerves causing the pain should be removed, which may cause the spine to become unstable. Your surgeon can implant the motion-preserving coflex device directly after a surgical decompression to help keep your spine stable. 

    In a European study, decompression with interlaminar stabilization using the coflex device was compared to decompression alone. The coflex device proved to extend the durability and sustainability of a decompression procedure out to two years. The coflex patients experienced: 

    • Superior composite clinical results (combination of 4 clinically relevant factors: disability improvement, neurological maintenance or improvement, no subsequent interventions, no device related complications) (P<0.05) 
    • Superior walking distance improvement (2.4x more compared to decompression alone) (P<0.05) 
    • Maintenance of foraminal height and disc height (allowing nerves to exit spinal canal freely) 
    • Significantly less epidural steroid injections post-surgery (decompression patients had 3.3x more) (P<0.05) 

    Clinical cases are unique and individual results may vary.  

    BENEFITS VS. FUSION3 

    Fusion is appropriate for many patients; however, motion is lost at both the treated and adjacent segments, multiple pieces of hardware and bone graft are required, and the recovery process can be long and difficult. Your surgeon can offer the coflex device as an alternative to fusion for moderate to severe lumbar spinal stenosis with <Grade I spondylolisthesis patients. 

    In a U.S. FDA study, decompression with interlaminar stabilization using the coflex device was compared to pedicle screw fusion. The coflex device proved to be a viable alternative treatment option compared to pedicle screw fusion out to 5 years, and results showed that coflex patients performed as good as if not better in all clinical measurements. The coflex patients experienced: 

    • Leg and back pain relief (both immediately and long-term) 
    • Less time in the operating room, less blood loss, and fewer days in the hospital 
    • Faster relief of symptoms and quicker recovery (pain and function measurements) 
    • Maintenance of range of motion at both treated and adjacent segments 

    Clinical cases are unique and individual results may vary. 

    1. Musacchio, M. (2016). Evaluation of decompression and Interlaminar Stabilization compared with decompression and fusion for the treatment of lumbar spinal stenosis: 5 year follow-up of a prospective, randomized, controlled trial. International Journal of Spine Surgery.; Schmidt, S. (2018). Prospective, randomized, multicenter study with 2-year follow-up to compare the performance of decompression with and without interlaminar stabilization. Journal of Neurosurgery. 
    2. Schmidt, S. (2018). Prospective, randomized, multicenter study with 2-year follow-up to compare the performance of decompression with and without interlaminar stabilization. Journal of Neurosurgery. 
    3. Musacchio, M. (2016). Evaluation of decompression and Interlaminar Stabilization compared with decompression and fusion for the treatment of lumbar spinal stenosis: 5 year follow-up of a prospective, randomized, controlled trial. International Journal of Spine Surgery. 
    4. FDA PMA P110008, October 2012. 
  • nanOss 3D® Plus Advanced Bone Graft Substitute
    A preformed strip composed of osteoconductive nano-structured hydroxyapatite combined with an engineered extracellular matrix bioscaffold that mimics a natural bone growth solution....

    • Improved Handling: 
      • Maintains graft integrity 
      • Pliable and cohesive 
      • Resists puncture 
      • Soaks and holds BMA 
    • nanOss 3D Plus ABGS is a synthetic bone graft substitute demonstrating a 97% or greater fusion rate.1,2,3,4 
    • Nano-structured HA is similar to bone in size, shape and composition, which increases its potential to remodel into new bone. 

    1. nanOss 3D ABGS: Epstein NE.High posterior cervical fusion rates with iliac autigraft and nanOss/bone marrow aspirate. Surg Neurol Int 2017;8:I52 
    2. nanOss 3D ABGS: Epstein NE. Epstein NE. High lumbar noninstrumented fusion rates using lamina autograft and nanOss/bone marrow aspirate. Surg Neurol Int 2017;8: I53.  
    3. nanOss 3D ABGS: Epstein NE. Preliminary documentation of the comparable efficacy of vitoss versus NanOss bioactive as bone graft expanders for posterior cervical fusion. Surg Neurol Int 2015;6:S164-71.  
    4. nanOss 3D ABGS: Epstein NE. Preliminary study showing safety/efficacy of nanoss bioactive versus vitoss as bone graft expanders for lumbar noninstrumented fusions. Surg Neurol Int 2015;6:S318-22. 

  • Fortilink® IBF Systems w/ TETRAfuse® 3D Technology
    3D printed TETRAfuse 3D Technology - Participates in fusion¹† - Bone-like mechanical properties¹ - Radiolucent - Antibacterial characteristics2†...

  • Fortilink®-A IBF System with TETRAfuse® 3D Technology 

    • Multiple size offerings 
    • Patterned graft window designed to aid in bone-to-implant osseointegration 
    • Hyperlordotic offering to help restore sagittal alignment 

    Fortilink®-C IBF System with TETRAfuse® 3D Technology 

    • Three radiographic markers facilitate visual confirmation of anterior/posterior position and lateral edges of implant 
    • 6° built-in lordotic angle  
    • Convex implant shape designed to match contours of endplates 
    • Multiple footprints with heights from 5 to 11mm 
    • Intended to be used with autograft and/or cancellous or corticocancellous allograft in one (1) or two (2) contiguous levels (cervical IBF) 

    Fortilink®-L IBF System with TETRAfuse® 3D Technology 

    • Large footprint offering 
    • Patterned graft window designed to aid in bone-to-implant osseointegration 
    • Unique anti-migration teeth pattern to aid in migration resistance 
    • Intended to be used with autograft and/or allograft in two (2) contiguous levels 

    Fortilink®-TS IBF System with TETRAfuse® 3D Technology 

    • Patterned graft window designed to aid in bone-to-implant osseointegration 
    • Designed for a unilateral or bilateral approach 
    • Grafts available from 8 to 17mm, in 1mm increments 
    • Parallel and 6° lordotic options 
    • Highly visible tantalum markers 
    • Intended to be used with autograft and/or allograft comprised of cancellous and/or corticocancellous bone graft as indicated in product labeling 

    * Performance data from animal studies may not be representative of performance in humans.  

    † Lab data may not be representative of the effects with all bacteria or performance when implanted in humans. Staphylococcus epidermidis and Pseudomonas aeruginosa were subject bacterial strains in this study.  

    1. Data on file at RTI Surgical, Inc. Animal and invitro data may not be representative of clinical experience.  
    2. Wang M, Bhardwj, Webster T: Antibacterial properties of PEKK for orthopedic applications. Int’l Journal of Nanomedicine. 2017: 12 6471-6476 
  • Streamline® TL Spinal Fixation System
    The Streamline® TL Spinal Fixation System allows a rigid construct to be created in the thoracolumbar spine using pedicle screws, set screws, rods and Streamline TL Crosslinks....

  • The system offers a broad range of implants and instruments, providing the ability to tailor treatment to a specific patient for a more efficient, streamlined, implant experience. 

    Pedicle Screws 

    • Polyaxial, fixed, and reduction screws available in multiple diameters and lengths 
    • Double lead thread design for faster implantation 
    • Ti-6Al-4V 

    Set Screws 

    • Designed to reduce incidence of cross-threading 
    • Use standard T25 drive mechanism 
    • Fit all screw sizes 
    • Ti-6Al-4V 

    Rods 

    • Ø5.5mm pre-bent and straight rods available in multiple lengths 
    • Titanium (Ti-6Al-4V) and cobalt chrome rods available 

    Crosslinks 

    • Variable and fixed options available in multiple lengths to accommodate a wide range of spinal anatomies 
    • Ti-6Al-4V 

    Connectors 

    • Open and closed rod-to-rod options 
    • Offset connectors available in multiple lengths 
    • Ti-6Al-4V 

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".